IMS Company Profiles - Report Buyer
IMS Company Profiles - Report Buyer IMS Company Profiles - Report Buyer
IMS COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING Sub sid iary of: Sandoz, Aus tria Phar ma ceu ti cal Sales: US$ 4-5 mil lion Prod ucts (% of Sales by Lead ing 5): 80-85% Ther a peu tic Classes (% of Sales by Lead ing 5): 85-90% Dose Forms (% of Sales by Lead ing 5): 95-100% Prin ci pal Prod ucts: LINEX (antidiarrheal mi cro-or gan ism) AMOKSIKLAV 2X (pen i cil lin broad spec trum) BRONCHO MUNAL (vac cine other) FERRUM LEK (iron plain/com bi na tion) EDICIN (an ti bac te rial other) Ther a peu tic Range: antidiarrheals, elec tro lyte re plac ers, in tes ti nal anti-inflammatorie s 37% antibacterials sys temic 31% vac cines 8% antianemic prep a ra tions 8% psycholeptics 4% Lead ing Dose Forms: cap sules 49% tab lets 23% coated tab lets 14% liq uids 7% in fu sions 4% NOVARTIS Full Name: Novartis Pharma Ser vices AG, Rep re - sen ta tive & Re gional Of fice Street Ad dress: Brivibas gatve 214b, 302 kab., LV-1039 Riga Tel: +371 6 788 7070 Fax: +371 6 788 7077 Home Page: www.mea.novartis.com Phar ma ceu ti cal Sales: US$ 4-5 mil lion Prod ucts (% of Sales by Lead ing 5): 55-60% Ther a peu tic Classes (% of Sales by Lead ing 5): 65-70% Dose Forms (% of Sales by Lead ing 5): 90-95% Prin ci pal Prod ucts: GLIVEC (antineoplastic other) SANDOSTATIN LAR (hor mone hy po tha lamic) LEPONEX (antipsychotic) FEMARA (cytostatic hor mone an tag o nist) SANDIMMUN NEORAL (immunosuppressive agent) Ther a peu tic Range: antineoplastics 24% immunosuppressive agents 15% hor mones pi tu itary and hy po tha lamic 13% psycholeptics 9% cytostatic hor mone ther apy 7% Lead ing Dose Forms: tab lets 45% coated tab lets 13% vi als 13% cap sules 11% in fu sions 10% NOVARTIS CON SUMER HEALTH Full Name: Novartis Con sumer Health Ser vices SA Street Ad dress: Kleistu 24, LV-1067 Riga Tel: +371 6 744 1300 Fax: +371 6 744 1301 De scrip tion: Rep re sen ta tive of fice. Pro moter. Prod uct ranges in clude: phar ma ceu ti cal prod ucts (branded, non-pre scrip tion), med i cal equip ment. Es tab lished 1997. 7 phar ma ceu ti cal employees in 2008. Rep re sen ta tives/De tail ers (Pharm, Num - ber): 1-10 (2008) Con tacts (Pharm): Chair man: Bjarne Pedersen; Gen eral Con tact: Atvars Kurats Phar ma ceu ti cal Sales: US$ 4-5 mil lion Prod ucts (% of Sales by Lead ing 5): 55-60% Ther a peu tic Classes (% of Sales by Lead ing 5): 85-90% Dose Forms (% of Sales by Lead ing 5): 90-95% Prin ci pal Prod ucts: THERAFLU NON-DROWS (cold prep a ra tion with - out anti-in fec tive) TAVEGYL (an ti his ta mine sys temic) THERAFLU NIGHT TIM (cold prep a ra tion with out anti-in fec tive) VIBROCIL (na sal prep a ra tion top i cal) OTRIVIN (na sal prep a ra tion top i cal) Ther a peu tic Range: cough and cold prep a ra tions 36% na sal prep a ra tions 22% an ti his ta mines sys temic 12% dermatological antifungals 9% antivaricosis/antihemorrhoidal prep a ra tions 9% Lead ing Dose Forms: pow ders/gran ules 34% liq uids 27% tab lets 13% gels/sols 10% creams 8% © 2009 IMS Health In cor po rated or its af fil i ates Page 184
IMS COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING LEBANON NOVARTIS Full Name: Novartis Pharma Ser vices AG, Bei rut Rep re sen ta tive Of fice Postal Ad dress: PO Box 11-3448, Bei rut Street Ad dress: Weav ers Cen ter, 7th Floor, Clemenceau Street, Bei rut Tel: +961 1 363260 Fax: +961 1 371567 Home Page: www.mea.novartis.com Phar ma ceu ti cal Sales: US$ 14-16 mil lion Prod ucts (% of Sales by Lead ing 5): 45-50% Ther a peu tic Classes (% of Sales by Lead ing 5): 60-65% Dose Forms (% of Sales by Lead ing 5): 90-95% Prin ci pal Prod ucts: CO DIOVAN (an gio ten sin-II an tag o nist com bi na - tion) DIOVAN (an gio ten sin-II an tag o nist plain) LESCOL (cho les terol/triglyceride reg u lat ing prep - a ra tion) FEMARA (cytostatic hor mone an tag o nist) TEGRETOL (antiepileptic) Ther a peu tic Range: renin-an gio ten sin sys tem agents 27% lipid-reg u lat ing/antiatheroma prep a ra tions 10% ophthalmologicals 9% cytostatic hor mone ther apy 7% anti rheu ma tics sys temic 7% Lead ing Dose Forms: coated tab lets 31% tab lets 31% cap sules 20% liq uids 10% sup pos i to ries 3% SANDOZ Full Name: Sandoz GmbH, Bei rut Rep re sen ta tive Of fice Postal Ad dress: PO Box 90-1599, Bei rut Street Ad dress: Horsh Kfoury, Badaro, Noueihed Bldg. 6th floor, Bei rut Tel: +961 1 382 490 Fax: +961 1 382 492 Email: sandoz@sandoz-lb.com Home Page: sandoz-lb.com De scrip tion: Rep re sen ta tive of fice. Pro moter. Prod uct ranges in clude: phar ma ceu ti cal prod ucts (branded, pre scrip tion, non-pre scrip tion). Es tab - lished 1998. 18 phar ma ceu ti cal employees in 2008. Rep re sen ta tives/De tail ers (Pharm, Num - ber): 12 (2008) Con tacts (Pharm): Chair man: Abir Alaeddine; Com mer cial Op er a tions: Reina Tannous, Hisham Joudieh; Gen eral Con tact: Chantal Ghawi Phar ma ceu ti cal Sales: US$ 2-3 mil lion Prod ucts (% of Sales by Lead ing 5): 75-80% Ther a peu tic Classes (% of Sales by Lead ing 5): 95-100% Dose Forms (% of Sales by Lead ing 5): 95-100% Prin ci pal Prod ucts: CURAM (pen i cil lin broad spec trum) OSPAMOX (pen i cil lin broad spec trum) OSPEN (pen i cil lin me dium/nar row spec trum) BIODROXIL (cephalosporin) SUPPLIN (amebicide) Ther a peu tic Range: antibacterials sys temic 82% antiparasitics 7% an ti bi ot ics, sulphonamides and antivirals top i cal 5% lipid-reg u lat ing/antiatheroma prep a ra tions 3% dermatological antifungals 2% Lead ing Dose Forms: coated tab lets 34% tab lets 30% liq uids 17% cap sules 12% oint ments 4% LITHUANIA HEXAL Full Name: Hexal AG, Co op er a tion Part ner/Rep - re sen ta tive Of fice Lith u a nia Street Ad dress: Zemaitijos g. 3-16, LT-01134 Vilnius Tel: +370 52 61 31 06/30 63 Fax: +370 52 61 30 66 Email: hexal@takas.lt Home Page: www.hexal.lt De scrip tion: Im porter, dis trib u tor, pro moter, sales/detailer. Prod uct ranges in clude: phar ma - ceu ti cal prod ucts (branded, unbranded, pre scrip - tion, non-pre scrip tion), hos pi tal pharmaceuticals, med i cal equip ment, oph thal mic prod ucts. Established 1996. Con tacts (Pharm): Gen eral Con tact: Tauras Endriukaitis © 2009 IMS Health In cor po rated or its af fil i ates Page 185
- Page 133 and 134: IMS COM PANY PRO FILES NOVARTIS Com
- Page 135 and 136: IMS COM PANY PRO FILES NOVARTIS Com
- Page 137 and 138: IMS COM PANY PRO FILES NOVARTIS Com
- Page 139 and 140: IMS COM PANY PRO FILES NOVARTIS Nov
- Page 141 and 142: IMS COM PANY PRO FILES NOVARTIS San
- Page 143 and 144: IMS COM PANY PRO FILES NOVARTIS als
- Page 145 and 146: IMS COM PANY PRO FILES NOVARTIS Nov
- Page 147 and 148: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 149 and 150: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 151 and 152: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 153 and 154: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 155 and 156: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 157 and 158: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 159 and 160: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 161 and 162: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 163 and 164: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 165 and 166: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 167 and 168: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 169 and 170: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 171 and 172: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 173 and 174: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 175 and 176: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 177 and 178: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 179 and 180: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 181 and 182: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 183: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 187 and 188: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 189 and 190: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 191 and 192: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 193 and 194: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 195 and 196: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 197 and 198: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 199 and 200: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 201 and 202: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 203 and 204: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 205 and 206: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 207 and 208: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 209 and 210: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 211 and 212: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 213 and 214: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 215 and 216: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 217 and 218: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 219 and 220: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 221 and 222: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 223 and 224: IMS COM PANY PRO FILES NOVARTIS SUB
- Page 225: IMS COM PANY PRO FILES APPENDIX - C
<strong>IMS</strong> COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING<br />
LEBANON<br />
NOVARTIS<br />
Full Name: Novartis Pharma Ser vices AG, Bei rut<br />
Rep re sen ta tive Of fice<br />
Postal Ad dress: PO Box 11-3448, Bei rut<br />
Street Ad dress: Weav ers Cen ter, 7th Floor,<br />
Clemenceau Street, Bei rut<br />
Tel: +961 1 363260<br />
Fax: +961 1 371567<br />
Home Page: www.mea.novartis.com<br />
Phar ma ceu ti cal Sales: US$ 14-16 mil lion<br />
Prod ucts (% of Sales by Lead ing 5): 45-50%<br />
Ther a peu tic Classes (% of Sales by Lead ing<br />
5): 60-65%<br />
Dose Forms (% of Sales by Lead ing 5):<br />
90-95%<br />
Prin ci pal Prod ucts:<br />
CO DIOVAN (an gio ten sin-II an tag o nist com bi na -<br />
tion)<br />
DIOVAN (an gio ten sin-II an tag o nist plain)<br />
LESCOL (cho les terol/triglyceride reg u lat ing prep -<br />
a ra tion)<br />
FEMARA (cytostatic hor mone an tag o nist)<br />
TEGRETOL (antiepileptic)<br />
Ther a peu tic Range:<br />
renin-an gio ten sin sys tem agents 27%<br />
lipid-reg u lat ing/antiatheroma prep a ra tions<br />
10%<br />
ophthalmologicals 9%<br />
cytostatic hor mone ther apy 7%<br />
anti rheu ma tics sys temic 7%<br />
Lead ing Dose Forms:<br />
coated tab lets 31%<br />
tab lets 31%<br />
cap sules 20%<br />
liq uids 10%<br />
sup pos i to ries 3%<br />
SANDOZ<br />
Full Name: Sandoz GmbH, Bei rut Rep re sen ta tive<br />
Of fice<br />
Postal Ad dress: PO Box 90-1599, Bei rut<br />
Street Ad dress: Horsh Kfoury, Badaro,<br />
Noueihed Bldg. 6th floor, Bei rut<br />
Tel: +961 1 382 490<br />
Fax: +961 1 382 492<br />
Email: sandoz@sandoz-lb.com<br />
Home Page: sandoz-lb.com<br />
De scrip tion: Rep re sen ta tive of fice. Pro moter.<br />
Prod uct ranges in clude: phar ma ceu ti cal prod ucts<br />
(branded, pre scrip tion, non-pre scrip tion). Es tab -<br />
lished 1998. 18 phar ma ceu ti cal employees in<br />
2008.<br />
Rep re sen ta tives/De tail ers (Pharm, Num -<br />
ber): 12 (2008)<br />
Con tacts (Pharm): Chair man: Abir Alaeddine;<br />
Com mer cial Op er a tions: Reina Tannous, Hisham<br />
Joudieh; Gen eral Con tact: Chantal Ghawi<br />
Phar ma ceu ti cal Sales: US$ 2-3 mil lion<br />
Prod ucts (% of Sales by Lead ing 5): 75-80%<br />
Ther a peu tic Classes (% of Sales by Lead ing<br />
5): 95-100%<br />
Dose Forms (% of Sales by Lead ing 5):<br />
95-100%<br />
Prin ci pal Prod ucts:<br />
CURAM (pen i cil lin broad spec trum)<br />
OSPAMOX (pen i cil lin broad spec trum)<br />
OSPEN (pen i cil lin me dium/nar row spec trum)<br />
BIODROXIL (cephalosporin)<br />
SUPPLIN (amebicide)<br />
Ther a peu tic Range:<br />
antibacterials sys temic 82%<br />
antiparasitics 7%<br />
an ti bi ot ics, sulphonamides and antivirals top i cal<br />
5%<br />
lipid-reg u lat ing/antiatheroma prep a ra tions 3%<br />
dermatological antifungals 2%<br />
Lead ing Dose Forms:<br />
coated tab lets 34%<br />
tab lets 30%<br />
liq uids 17%<br />
cap sules 12%<br />
oint ments 4%<br />
LITHUANIA<br />
HEXAL<br />
Full Name: Hexal AG, Co op er a tion Part ner/Rep -<br />
re sen ta tive Of fice Lith u a nia<br />
Street Ad dress: Zemaitijos g. 3-16, LT-01134<br />
Vilnius<br />
Tel: +370 52 61 31 06/30 63<br />
Fax: +370 52 61 30 66<br />
Email: hexal@takas.lt<br />
Home Page: www.hexal.lt<br />
De scrip tion: Im porter, dis trib u tor, pro moter,<br />
sales/detailer. Prod uct ranges in clude: phar ma -<br />
ceu ti cal prod ucts (branded, unbranded, pre scrip -<br />
tion, non-pre scrip tion), hos pi tal pharmaceuticals,<br />
med i cal equip ment, oph thal mic prod ucts.<br />
Established 1996.<br />
Con tacts (Pharm): Gen eral Con tact: Tauras<br />
Endriukaitis<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 185